U.S. House lawmakers say the FDA should not rely on Chinese clinical-trial data without recent inspections, citing opaque reporting of serious adverse events in high-risk biomedical research
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
U.S. lawmakers are urging the Food and Drug Administration to heavily scrutinize clinical-trial data originating from China, following the previously undisclosed deaths of three patients in Chinese gene-editing and cell-therapy studies.
Exclusive: Two GOP lawmakers call on FDA to increase scrutiny of Chinese trial data following deaths
Three deaths in China shake trust in the country's speedy clinical trial system
Why a Texas congressman believes Chinese biotechs are 'beating us on our ground game'
Amgen, medical centers diverge on potential conflicts in FDA pilot to speed early drug trials
VIDEO: Calabrese discusses compounded drugs, US probe into Chinese clinical trials
GOP Reps. Moolenaar & Cline urge FDA's Diamantas to reject Chinese clinical trial data unless sites are audited annually, citing…
Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing a rethink
The death of a six-year-old patient in an investigator-initiated study highlights systemic vulnerabilities in ethics reviews,…
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in…
China has tightened regulations on investigator-initiated trials, with consequences not just for Chinese researchers but some…
The U.S. House Select Committee on China has opened investigations into five pharmaceutical companies regarding their clinical…
